$2.76M in average volume shows that Amicus Therapeutics Inc (FOLD) is heading in the right direction

On Thursday, Amicus Therapeutics Inc (NASDAQ: FOLD) remained unchanged from the previous day of trading 1.94% from the last session, before settling in for the closing price of $6.70. Price fluctuations for FOLD have ranged from $6.20 to $12.65 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 24.32%. Company’s average yearly earnings per share was noted 113.44% at the time writing. With a float of $296.87 million, this company’s outstanding shares have now reached $299.04 million.

Let’s determine the extent of company efficiency that accounts for 499 employees. In terms of profitability, gross margin is 89.98%, operating margin of 4.71%, and the pretax margin is -5.44%.

Amicus Therapeutics Inc (FOLD) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Amicus Therapeutics Inc is 3.38%, while institutional ownership is 97.65%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,000. In this transaction President and CEO of this company sold 400 shares at a rate of $10.00, taking the stock ownership to the 1,150,657 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Director proposed sale 400 for $9.85, making the entire transaction worth $3,940.

Amicus Therapeutics Inc (FOLD) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 113.44% per share during the next fiscal year.

Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators

Check out the current performance indicators for Amicus Therapeutics Inc (FOLD). In the past quarter, the stock posted a quick ratio of 2.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.97.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach 0.32 in one year’s time.

Technical Analysis of Amicus Therapeutics Inc (FOLD)

Looking closely at Amicus Therapeutics Inc (NASDAQ: FOLD), its last 5-days average volume was 3.23 million, which is a jump from its year-to-date volume of 2.74 million. As of the previous 9 days, the stock’s Stochastic %D was 38.05%. Additionally, its Average True Range was 0.38.

During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 15.16%, which indicates a significant decrease from 29.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.84% in the past 14 days, which was higher than the 35.66% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.59, while its 200-day Moving Average is $10.00. However, in the short run, Amicus Therapeutics Inc’s stock first resistance to watch stands at $6.93. Second resistance stands at $7.03. The third major resistance level sits at $7.18. If the price goes on to break the first support level at $6.68, it is likely to go to the next support level at $6.53. Should the price break the second support level, the third support level stands at $6.43.

Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats

There are currently 307,240K shares outstanding in the company with a market cap of 2.10 billion. Presently, the company’s annual sales total 528,300 K according to its annual income of -56,110 K. Last quarter, the company’s sales amounted to 149,710 K and its income totaled 14,740 K.